LCM
PTLA

Laurion Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Laurion Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-125,000
Closed -$7.02M – 2001
2017
Q2 		$7.02M Buy
+125,000
New +$5.01M 0.04% 424

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Laurion Capital Management's PTLA Position: Q4 2017 in Review

Laurion Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2017, closing a stake of 450,118 shares — an estimated $24.3M sold.

Laurion Capital Management first reported a position in PTLA in Q4 2013 and held it in 4 quarters. The position peaked at $24.3M in Q3 2017. 215 funds tracked by Wall St. Rank hold PTLA as of Q4 2017.

  • Laurion Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Laurion Capital Management sold 450,118 Portola Pharmaceuticals, Inc. shares in Q4 2017, an estimated $24.3M.
  • Laurion Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q4 2013 and held it in 4 quarters.
  • Laurion Capital Management's Portola Pharmaceuticals, Inc. position peaked at $24.3M in Q3 2017.
  • 215 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2017.

Based on Laurion Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.